Edith A. Pérez, MD
OFFLINE

Edith A. Pérez, MD

1863
Edith A. Pérez, MD
Professor of Medicine, Hematology / Oncology
904-953-2000
Mayo Clinic – Jacksonville, FL

Edith A. Perez, M.D., is the deputy director at large for Mayo Clinic Cancer Center in Jacksonville, Fla., and the Serene M. and Frances C. Durling Professor at Mayo Clinic College of Medicine. She also serves as chair of the Mayo Clinic Breast Cancer Translational Genomics Program and the Breast Cancer Specialty Council.

Dr. Perez is a cancer specialist and an internationally known translational researcher. Her roles extend nationally, including group vice chair for the Alliance for Clinical Trials in Oncology and other positions within the American Association for Cancer Research, the American Society of Clinical Oncology and the National Cancer Institute.

She has authored more than 690 research articles in journals, books and abstracts. Dr. Perez is invited frequently to lecture at national and international meetings and serves on the editorial boards of multiple academic journals.  Dr. Perez is developing a wide range of clinical trials exploring targeted therapeutic agents for the treatment and prevention of breast cancer.  She is also leading studies to evaluate the role of genetic biomarkers in the development, aggressiveness and therapeutic efficacy of therapies for breast cancer.

1. Norton N, Olson RM, Pegram MD, Tenner KS, Ballman KV, Clynes R, Knutson KL,Perez EA. Association Studies of Fcgamma Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831. Cancer Immunol Res. 2014 Jul 02. 

2. Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, Patt DA, Perez EA, Perlmutter J, Ramakrishna N, Winer EP. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2014 Jul 1; 32(19):2078-99. Epub 2014 May 05. 

3. Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Gonzalez-Angulo AM, Kirshner JJ, Krop I, Levinson J, Modi S, Patt DA,Perez EA, Perlmutter J, Winer EP, Lin NU. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2014 Jul 1; 32(19):2100-8. Epub 2014 May 05. 

4. Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP. Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014 Jun 16. 

5. Northfelt DW, Allred JB, Liu HS, Hobday TJ, Rodacker MW, Lyss AP, Fitch TR, Perez EA. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer. American Journal Of Clinical Oncology-cancer Clinical Trials. 2014 Apr; 37(2):167-71. 

6. Perez EA, Cortes J, Gonzalez-Angulo AM, Bartlett JM. HER2 testing: current status and future directions. Cancer Treat Rev. 2014 Mar; 40(2):276-84. Epub 2013 Sep 11 

7. McCullough AE, Dell'orto P, Reinholz MM, Gelber RD, Dueck AC, Russo L, Jenkins RB, Andrighetto S, Chen B, Jackisch C, Untch M, Perez EA, Piccart-Gebhart MJ, Viale G. Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. Breast Cancer Res Treat. 2014 Feb; 143(3):485-92. Epub 2014 Jan 07. 

8. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014 Feb; 138(2):241-56. Epub 2013 Oct 07. 

9. Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Rothe F, Metallo J, Rouas G, Payne RE, Coombes RC, Teufel I, Andergassen U, Apostolaki S, Politaki E, Mavroudis D, Bessi S, Pestrin M, Di Leo A, Campion M, Reinholz M, Perez E, Piccart M, Borgen International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Res. 2014; 16(2):R43. 

10. Roy V, Pockaj BA, Allred JB, Apsey H, Northfelt DW, Nikcevich D, Mattar B, Perez EA. A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338. Am J Clin Oncol. 2013 Dec; 36(6):540-4.

U54 Collaborators

Universidad de Puerto RicoThe University of Texas – MD Anderson Cancer CenterNational Cancer InstituteCenter for Reduce Cancer Health Disparities